SWOG clinical trial number
SWOG-9450
Prostate Cancer Intervention Versus Observation Trial
Closed
Phase
Published
Abbreviated Title
Local Prostate
Activated
05/01/1995
Closed
11/30/2001
Research committees
Genitourinary Cancer
Eligibility Criteria Expand/Collapse
Age < /= 75 yrs; Clinically localized tissue documented adenoca. of the prostate, (T1 a,b,c, - T2 a,b,c, NX, M0); Diagnosis of CAP within previous 6 mo; PSA < 50 ng/ml,(if currently taking finasteride, PSA < 25 ng/ml); no prior pelvic RT, chemo, anti-androgen or androgen deprivation therapy except 5-alpha-reductase inhibitors; no prior surg. other than TURP/TUIP/dilation/simple prostatectomy; no current estrogen or androgen blocking therapy; no evidence of metastatic dz., no significant medical conditions or high surgical risks (MI within last 6 mo, unstable angina, severe CHF pulmonary or hepatic dz, see p. 31 of the Manual of Operations for complete description).
Publication Information Expand/Collapse
2012
Prostate Cancer - uncertainty and a way forward
PMid: PMID22808963 | PMC number: n/a (commentary)
1997
The prostate cancer intervention versus observation trial (PIVOT).
Other Clinical Trials
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase